- Home
- MBWM vs FULC Comparison
MBWM vs FULC Comparison
Compare MBWM & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBWM | FULC |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 863.0M | 718.4M |
| IPO Year | 1997 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MBWM | FULC |
|---|---|---|
| Price | $49.22 | $7.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $53.63 | $16.38 |
| AVG Volume (30 Days) | 79.7K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ 10.95 | N/A |
| EPS | ★ 5.47 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.28 | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | $9.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.76 | $2.32 |
| 52 Week High | $55.77 | $15.74 |
Technical Indicators
Market Signals| Indicator | MBWM | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 33.33 |
| Support Level | $43.14 | $7.40 |
| Resistance Level | $50.36 | $8.50 |
| Average True Range (ATR) | 1.69 | 0.79 |
| MACD | -0.53 | -0.19 |
| Stochastic Oscillator | 12.59 | 4.21 |
Price Performance
Historical ComparisonAbout MBWM Mercantile Bank Corporation
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.